Seagen touts Adcetris early-stage Lymphoma data with 93% complete remission
Seattle-based biotech company Seagen appears to have found success with a drug in its phase II trials of early-stage classical Hodgkin lymphoma, with 93% of subjects experiencing complete remission of the cancer.
The drug – Adcetris — was used with other agents to treat patients in the trials. The FDA approved Adcetris for treatment of cHL patients in November 2022.
Seagen is in the process of being acquired by Pfizer, announced earlier this year, for $43 billion. Adcetris will be added to Pfizer’s drug portfolio once the acquisition is finalized in late 2023 or early 2024.